MTOR and renal carcinoma: Everolimus and temsirolimus, mTOR inhibitors, have been approved by the FDA for the treatment of gastrointestinal, lung, and renal cancers, whereas rapamycin, another mTOR inhibitor, increased the median lifespan of genetically heterogeneous mice by approximately 25% (in both sexes, Miller et al., 2014), and its impact on aging has been investigated in clinical trial setting (NCT04488601, NCT03072485).